Accomplished Industry Veteran, Satrajit Misra, Joins QT Imaging as Chief Commercial Officer

QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (OTCQB: QTIH), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce the appointment of Satrajit Misra as the Company’s Chief Commercial Officer (“CCO”).

Mr. Misra’s appointment underscores QTI’s commitment to innovation, clinical excellence, and commercial execution in delivering accessible, radiation-free, contrast-free, and compression-free breast imaging technologies for women worldwide.

“We are thrilled to welcome Satrajit as our CCO as we advance commercialization and pivot toward a SaaS and biomarker-driven franchise,” said Dr. Raluca Dinu, CEO of QTI. “Satrajit’s deep domain experience in building and scaling state-of-the-art medical imaging franchises, his strong relationships among leading radiology and oncology thought leaders, and his proven success in driving growth and innovation across imaging and MedTech enterprise, will be instrumental as we accelerate adoption of our innovative diagnostic technologies.”

A seasoned executive with three decades of progressive leadership in Radiology, Oncology and Molecular Imaging, Mr. Misra is recognized for his expertise in scaling complex businesses, leading acquisitions and integrations, and forging high-impact alliances to expand into white-space markets. He comes to QT Imaging from the Company’s strategic partner, Canon Medical Systems USA (“Canon USA”), where he most recently served as Executive Senior Vice President, Chief Sales and Marketing Officer. Prior to first joining Canon USA in 2012, Mr. Misra was Philips’ Head of Business Development and Marketing, and before that, Siemens Healthcare’s Director of Business Management. Mr. Misra has a Bachelor of Science and a Bachelor of Technology in applied physics from the University of Calcutta in India, attended the School of Business and Economic Studies at the University of Leeds in the United Kingdom, and has a certificate in negotiation from Harvard Business School in the United States.

In this newly created c-suite role at QT Imaging, Mr. Misra will drive commercial scale-up and clinical partnerships, positioning the company as a modality of choice for supplemental breast screening and biomarker-driven precision diagnostics.

“I’m excited to join QTI at this pivotal inflection point as we bring our transformative breast imaging technology to scale and redefine standards in early detection and precision diagnostics,” said Mr. Misra. “While I worked closely with Raluca and her team via the Company’s ongoing strategic partnership with Cannon USA, it was captivating to watch the scale, scope and speed with which QTI had already begun to transform breast health management for the potential benefit of millions of patients. I look forward to working with the QTI team to develop and expand the product pipeline, accelerate growth, and enhance value for our shareholders.”

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including its transformation from a hardware-focused startup to a biomarker-driven AI imaging company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110081345/en/